Vancouver, British Columbia–(Newsfile Corp. – February 3, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by the local Dutch ethics committee of…


Previous articleSmall Pharma Reports Fiscal Third Quarter 2021 Highlights
Next articleSilo Pharma Extends Exclusive Option Agreement for Homing Peptides